Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)

San Donato Group (GSD)

Status: Active, not recruiting

Conditions: Coronavirus Infections

Treatments: Other: biological bank

Study type: Observational

Funder types: Other

Identifiers

NCT05276388

COVID BioVAC

Details and patient eligibility

About

Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)

Full description

The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.

Enrollment: 1,100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age ≥18 years
• Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others
• Signing of informed consent from January to March 2021

Exclusion criteria

• none